

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class mail in an envelope addressed to: Box AF, Assistant Commissioner for Patents, Washington, D.C. 20231  
On December 19, 2000

By: [Signature]

#16/R.T.  
C (N.E.)

PATENT

Attorney Docket No.: 14538A-005110US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

ANDREW KOFF et al.

Application No.: 08/973,823

Filed: December 10, 1997

For: METHODS FOR ENHANCING  
ANIMAL GROWTH AND CELL  
PROLIFERATION BY  
ELIMINATION OF THE CYCLIN-  
DEPENDENT KINASE  
INHIBITOR FUNCTION OF  
P27<sup>Kip1</sup>

Examiner: M. Schmidt

Group Art Unit: 1635

**AMENDMENT AFTER FINAL**

**Box AF**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

In response to the Final Office Action mailed June 21, 2000, please amend this application as follows:

**IN THE CLAIMS:**

Please cancel claims 1-13 without prejudice to Applicants' right to continue to prosecute the subject matter of these claims in a related, co-pending application.

- 1 14. (Twice Amended) A method for increasing the proliferation of  
2 thymocytes in a non-human [an] animal [which comprises] comprising altering the gene  
3 encoding p27<sup>Kip1</sup> in a somatic cell of the animal [treating the animal] to cause a functional  
4 deficiency of [eliminate the] cyclin-dependent kinase inhibitor function of p27<sup>Kip1</sup>, thereby  
5 increasing the proliferation of thymocytes in the animal.

OK To  
Enter  
5/20/01  
mms

not completely  
eliminated

in the cell  
of all the  
11 of the  
12 mg